Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Brain Neoplasms 2Vaping 1Tobacco Use Disorder 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Endometrial Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 29fludarabine phosphate 22Whole-Body Irradiation 20Mycophenolic Acid 20fludarabine 19asciminib 19nilotinib 16Tacrolimus 13Imatinib Mesylate 13Melphalan 11Dasatinib 9Sirolimus 8Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Granulocyte Colony-Stimulating Factor 7Busulfan 7bosutinib 6Mesna 6Cyclosporine 6ponatinib 5Stem Cell Transplantation 5Filgrastim 5venetoclax 4ruxolitinib 4blinatumomab 4Specimen Handling 4Cyclosporins 4thymoglobulin 3Bone Marrow Transplantation 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × BID protein, human × 1 year × Clear all
NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Novartis

Phase 3 Completed
199 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡